Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 8;16(10):1791.
doi: 10.3390/cancers16101791.

Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis

Meghana Kesireddy  1 , Lina Elsayed  1 , Valerie K Shostrom  2 , Priyal Agarwal  1 , Samia Asif  1 , Amulya Yellala  1 , Jairam Krishnamurthy  1
Affiliations

Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis

Meghana Kesireddy et al. Cancers (Basel). .

Abstract

Background: Metastatic triple-negative breast cancer (TNBC) is aggressive with poor median overall survival (OS) ranging from 8 to 13 months. There exists considerable heterogeneity in survival at the individual patient level. To better understand the survival heterogeneity and improve risk stratification, our study aims to identify the factors influencing survival, utilizing a large patient sample from the National Cancer Database (NCDB).

Methods: Women diagnosed with metastatic TNBC from 2010 to 2020 in the NCDB were included. Demographic, clinicopathological, and treatment data and overall survival (OS) outcomes were collected. Kaplan-Meier curves were used to estimate OS. The log-rank test was used to identify OS differences between groups for each variable in the univariate analysis. For the multivariate analysis, the Cox proportional hazard model with backward elimination was used to identify factors affecting OS. Adjusted hazard ratios and 95% confidence intervals are presented.

Results: In this sample, 2273 women had a median overall survival of 13.6 months. Factors associated with statistically significantly worse OS included older age, higher comorbidity scores, specific histologies, higher number of metastatic sites, presence of liver or other site metastases in those with only one metastatic site (excluding brain metastases), presence of cranial and extra-cranial metastases, lack of chemotherapy, lack of immunotherapy, lack of surgery to distant sites, lack of radiation to distant sites, and receipt of palliative treatment to alleviate symptoms. In the multivariate analysis, comorbidity score, histology, number of metastatic sites, immunotherapy, and chemotherapy had a statistically significant effect on OS.

Conclusions: Through NCDB analysis, we have identified prognostic factors for metastatic TNBC. These findings will help individualize prognostication at diagnosis, optimize treatment strategies, and facilitate patient stratification in future clinical trials.

Keywords: clinicopathological factors; cox proportional hazard model; demographic factors; metastatic triple-negative breast cancer; multivariate analysis; national cancer database; overall survival; prognostic factors; treatment factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves of the five significant variables in the multi-variate analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010;363:1938–1948. doi: 10.1056/NEJMra1001389. - DOI - PubMed
    1. Trivers K.F., Lund M.J., Porter P.L., Liff J.M., Flagg E.W., Coates R.J., Eley J.W. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071–1082. doi: 10.1007/s10552-009-9331-1. - DOI - PMC - PubMed
    1. Nam Y.H. A Study on the Factors and Prediction Model of Triple-Negative Breast Cancer for Public Health Promotion. Diagnostics. 2023;13:3486. doi: 10.3390/diagnostics13223486. - DOI - PMC - PubMed
    1. Kassam F., Enright K., Dent R., Dranitsaris G., Myers J., Flynn C., Fralick M., Kumar R., Clemons M. Survival outcomes for patients with metastatic triple-negative breast cancer: Implications for clinical practice and trial design. Clin. Breast Cancer. 2009;9:29–33. doi: 10.3816/CBC.2009.n.005. - DOI - PubMed

LinkOut - more resources